CBR1 and Alzheimer disease: Theoretically, they could represent a valuable alternative to orthosteric modulators because they could provide fine-tuning of microglial CBR signaling and, because of the development of cannabinoid-based drugs for the treatment of AD, would be associated with fewer unwanted effects and an effective pharmacological profile [102].